Read More Pharma Industry News Can GSK’s Exdensur transform asthma biologics with just two doses per year? GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy. byPallavi MadhirajuDecember 17, 2025